![David Beadle](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Beadle
Director/Board Member at Phico Therapeutics Ltd.
Profile
David Beadle is a professional who has worked as a Non-Executive Director at Phico Therapeutics Ltd.
since 2019.
Prior to this, he worked as a Director & Chief Business Officer at Revolo Biotherapeutics Ltd.
and as a Research Analyst at UBS Ltd.
Mr. Beadle completed his undergraduate degree at the University of Birmingham.
David Beadle active positions
Companies | Position | Start |
---|---|---|
Phico Therapeutics Ltd.
![]() Phico Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Phico Therapeutics Ltd. develops antibiotic bacteria resistant technology. Its products include SASPject PT1.2 used for intra-nasal decolonization, SASPject PT3.1 used for intra-abdominal infections and SASPject PT4 used for both the infections. The company was founded by Dr. Heather Fairhead and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | 15/01/2019 |
Former positions of David Beadle
Companies | Position | End |
---|---|---|
Revolo Biotherapeutics Ltd.
![]() Revolo Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Revolo Biotherapeutics Ltd. develops immunologic and inflammatory medications. It develops disease resetting therapeutics for immuno-inflammatory diseases. The company was founded in 2011 and is headquartered in Stevenage, the United Kingdom. | Director/Board Member | - |
UBS Ltd. (Broker)
![]() UBS Ltd. (Broker) Investment Banks/BrokersFinance UBS Ltd. (Broker) is the Great Britain-based brokerage division of UBS Ltd.,the wholly-owned subsidiary of Switzerland-based UBS AG (SWX: UBSN; NYSE: UBS). Established in 1975, the firm is located in London. UBS Ltd.'s business is organized in three departments: fixed-income, rates and currencies; equity and investment banking. UBS Ltd. (Broker) engages in equity trading, equity derivatives and equity-linked products. The equity research department covers a diverse range of sectors globally and also supplies macroeconomic analysis, quantitative and derivative research. The fixed-income, rates and currency business covers credit, rates, commodities including energy and metals, municipal bonds, Forex and cash and collateral trading globally. Their investment banking activities include analysis, structuring, transaction negotiation and communication. | Analyst-Equity | - |
Training of David Beadle
University of Birmingham | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
UBS Ltd. (Broker)
![]() UBS Ltd. (Broker) Investment Banks/BrokersFinance UBS Ltd. (Broker) is the Great Britain-based brokerage division of UBS Ltd.,the wholly-owned subsidiary of Switzerland-based UBS AG (SWX: UBSN; NYSE: UBS). Established in 1975, the firm is located in London. UBS Ltd.'s business is organized in three departments: fixed-income, rates and currencies; equity and investment banking. UBS Ltd. (Broker) engages in equity trading, equity derivatives and equity-linked products. The equity research department covers a diverse range of sectors globally and also supplies macroeconomic analysis, quantitative and derivative research. The fixed-income, rates and currency business covers credit, rates, commodities including energy and metals, municipal bonds, Forex and cash and collateral trading globally. Their investment banking activities include analysis, structuring, transaction negotiation and communication. | Finance |
Revolo Biotherapeutics Ltd.
![]() Revolo Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Revolo Biotherapeutics Ltd. develops immunologic and inflammatory medications. It develops disease resetting therapeutics for immuno-inflammatory diseases. The company was founded in 2011 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Phico Therapeutics Ltd.
![]() Phico Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Phico Therapeutics Ltd. develops antibiotic bacteria resistant technology. Its products include SASPject PT1.2 used for intra-nasal decolonization, SASPject PT3.1 used for intra-abdominal infections and SASPject PT4 used for both the infections. The company was founded by Dr. Heather Fairhead and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
- Stock Market
- Insiders
- David Beadle